The Fear of COVID-19 Scale: Development and Initial Validation

Daniel Kwasi Ahorsu, Chung-Ying Lin, Vida Imani, Mohsen Saffari, Mark D Griffiths, Amir H Pakpour, Daniel Kwasi Ahorsu, Chung-Ying Lin, Vida Imani, Mohsen Saffari, Mark D Griffiths, Amir H Pakpour

Abstract

Background: The emergence of the COVID-19 and its consequences has led to fears, worries, and anxiety among individuals worldwide. The present study developed the Fear of COVID-19 Scale (FCV-19S) to complement the clinical efforts in preventing the spread and treating of COVID-19 cases.

Methods: The sample comprised 717 Iranian participants. The items of the FCV-19S were constructed based on extensive review of existing scales on fears, expert evaluations, and participant interviews. Several psychometric tests were conducted to ascertain its reliability and validity properties.

Results: After panel review and corrected item-total correlation testing, seven items with acceptable corrected item-total correlation (0.47 to 0.56) were retained and further confirmed by significant and strong factor loadings (0.66 to 0.74). Also, other properties evaluated using both classical test theory and Rasch model were satisfactory on the seven-item scale. More specifically, reliability values such as internal consistency (α = .82) and test-retest reliability (ICC = .72) were acceptable. Concurrent validity was supported by the Hospital Anxiety and Depression Scale (with depression, r = 0.425 and anxiety, r = 0.511) and the Perceived Vulnerability to Disease Scale (with perceived infectability, r = 0.483 and germ aversion, r = 0.459).

Conclusion: The Fear of COVID-19 Scale, a seven-item scale, has robust psychometric properties. It is reliable and valid in assessing fear of COVID-19 among the general population and will also be useful in allaying COVID-19 fears among individuals.

Keywords: COVID-19; Fear; Fear of COVID-19 Scale; Iran; Psychometrics.

Conflict of interest statement

Conflict of InterestThe authors declare that they do not have any interests that could constitute a real, potential or apparent conflict of interest with respect to their involvement in the publication. The authors also declare that they do not have any financial or other relations (e.g., directorship, consultancy or speaker fee) with companies, trade associations, unions or groups (including civic associations and public interest groups) that may gain or lose financially from the results or conclusions in the study. Sources of funding are acknowledged.

© The Author(s) 2020.

References

    1. Ahmadzadeh M, Ghamarani A, Samadi M, Shamsi A, Azizollah A. The investigation of validity and reliability of a scale of perceived vulnerability to disease in Iran. British Journal of Social Sciences. 2013;1:43–51.
    1. Baud, D., Qi, X., Nielsen-Saines, K., Musso, D., Pomar, L., & Favre, G. (2020). Real estimates of mortality following COVID-19 infection. The Lancet Infectious Diseases. Retrieved from. 10.1016/S1473-3099(20)30195-X.
    1. Centers for Disease Control and Prevention (2020a). Coronavirus Disease 2019 (COVID-19): Manage anxiety & stress. Retrieved March 16, 2020, from: .
    1. Centers for Disease Control and Prevention (2020b). Coronavirus disease 2019 (COVID-19): Reducing stigma. Retrieved March 16, 2020, from: .
    1. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19) Drug Discoveries & Therapeutics. 2020;14(1):58–60. doi: 10.5582/ddt.2020.01012.
    1. Duncan LA, Schaller M, Park JH. Perceived vulnerability to disease: Development and validation of a 15-item self-report instrument. Personality and Individual Differences. 2009;47(6):541–546. doi: 10.1016/j.paid.2009.05.001.
    1. Guan, W. J., Ni, Z. Y., Hu, Y., Liang, W. H., Ou, C. Q., He, J. X., ... & Du, B. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 10.1056/NEJMoa2002032.
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Lin C-Y. Social reaction toward the 2019 novel coronavirus (COVID-19) Social Health and Behavior. 2020;3(1):1–2. doi: 10.4103/SHB.SHB_11_20.
    1. McCoach, D. B., Gable, R. K., & Madura, J. P. (2013). Review of the steps for designing an instrument. In Instrument development in the affective domain (pp. 277–284). New York: Springer.
    1. Montazeri A, Vahdaninia M, Ebrahimi M, Jarvandi S. The Hospital Anxiety and Depression Scale (HADS): Translation and validation study of the Iranian version. Health and Quality of Life Outcomes. 2003;1(1):14. doi: 10.1186/1477-7525-1-14.
    1. Pappas G, Kiriaze IJ, Giannakis P, Falagas ME. Psychosocial consequences of infectious diseases. Clinical Microbiology and Infection. 2009;15(8):743–747. doi: 10.1111/j.1469-0691.2009.02947.x.
    1. Ropeik D. The consequences of fear. EMBO Reports. 2004;5(Suppl 1):S56–S60. doi: 10.1038/sj.embor.7400228.
    1. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., ... & Zhao, Y. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA, 323(11), 1061–1069. 10.1001/jama.2020.1585.
    1. World Health Organization (2020). Coronavirus disease (COVID-2019): Situation report-54. Retrieved March 16, 2020, from: .
    1. Wu T-Y, Lin C-Y, Årestedt K, Griffiths MD, Broström A, Pakpour AH. Psychometric validation of the Persian nine-item Internet Gaming Disorder Scale-Short Form: Does gender and hours spent online gaming affect the interpretations of item descriptions? Journal of Behavioral Addictions. 2017;6(2):256–263. doi: 10.1556/2006.6.2017.025.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe